Truvian Sciences
Mar 31, 2020
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M
Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19. The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...
Read More...
Nov 21, 2019
GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion
Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the proceeds to invest in healthcare companies. Closure of the second round capped at USD 1.1 Billion (Euro 975 Million) is the l...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
